Great Place to Work® Designates Selexis as a Best Workplace in Switzerland for Fifth Straight Year
Read More
Bioprocess International (BPI) West, San Diego, USA | March 14 – 17, 2022
Bio Europe SPRING, Basel, Switzerland | March 28 – 31, 2022
Swiss Biotech Day, Basel, Switzerland | May 2 – 3, 2022
PEGS US Boston, Boston, USA | May 2 – 6, 2022
BioProcess International (BPI) Europe, Viena, Austria | May 17 – 20, 2022
Antibody Engineering EU, Amsterdam, Netherlands | June 7 – 9, 2022
BIO International Convention US, San Diego, USA | June 13 – 16, 2022
ESACT 27th meeting, Lisbon, Portugal | June 26 – 29, 2022
PEPTALK, San Diego, USA | January 17 – 19, 2022
BIO Partnering at JPM, USA | January 10 – 14, 2022
BIOFIT , Strasbourg, EMEA | December 7 – 9, 2021
BioPharma Expo (Interphex Japan), Japan | December 8 – 10, 2021
Antibody Engineering & Theraputics (US), USA | December 12 – 16, 2021
BioProcess International (BPI) Europe, Viena, Austria | December 1 – 2, 2021
Festival of Biologics - European, Basel, Switzerland | November 9 – 11, 2021
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 158 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Copyright© 2022 Selexis SA. All Rights Reserved.